Navigation Links
Lexicon Announces Commencement of Rights Offering to Stockholders
Date:11/22/2011

to initiate a pro rata rights offering to its stockholders.  Invus, L.P. and Invus C.V. will be required to exercise their basic subscription privileges in full and purchase at least 68,868,892 shares of common stock in the rights offering, subject to certain customary closing conditions, including the expiration or termination of any applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.  In light of the potential for the ownership percentage of Invus, L.P., Invus C.V. and their affiliates to increase to greater than 50% of Lexicon's outstanding common stock as a result of the rights offering, the parties have made the required filings for that purpose with the Premerger Notification Office of the Federal Trade Commission and the Antitrust Division of the Department of Justice.

Any questions from stockholders or requests for additional copies of the prospectus supplement and accompanying prospectus or other rights offering materials may be directed to BNY Mellon Shareowner Services, the information agent for the rights offering, at (800) 777-3674 from within the United States, Canada or Puerto Rico, or at (201) 680-6579 from outside the United States.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale is not permitted.  The offering of securities in the rights offering will be made only by means of the prospectus supplement and accompanying prospectus, copies of which may be obtained from BNY Mellon Shareowner Services as indicated above.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has four drug programs in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rhe
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lexicon to Present LX4211 Clinical and Preclinical Data at Diabetes Conference
2. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Third Quarter Results
3. Lexicon to Provide Clinical Pipeline Update and Report Third Quarter 2011 Financial Results
4. Lexicon Presents LX4211 Clinical Data at European Association for the Study of Diabetes Annual Meeting
5. Lexicon Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference
6. Lexicon Pharmaceuticals to Present at Stifel Nicolaus Healthcare Conference
7. Lexicon Pharmaceuticals to Present at the Wedbush 2011 Life Sciences Management Access Conference
8. Lexicon Announces Publication of Results From the Phase 2 Trial of LX1031 in Patients With Irritable Bowel Syndrome in Journal of Gastroenterology
9. Phase 2 Trial of Lexicons LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome
10. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Second Quarter Results
11. Lexicons IBS Drug Candidate, LX1033, Successfully Completes Phase 1 Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  Now available for sale, The ... support that prevents ankle sprains by cushioning the ankle ... fits securely around the outside of any shoe type ... comfort while still offering protection against sprains. With customers ...
(Date:1/23/2015)... N.Y. , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. ... its Phase I trial of Lixte,s lead compound, LB‑100, is ... John S. Kovach , M.D., the founder ... planned to be completed at a single site. Accrual of ...
(Date:1/23/2015)... 2015   Leatt Corporation  (OTCQB: LEAT), a global developer, ... forms of sports, including extreme motor sports, and whose ... that the UISP Lega Motociclismo Lombardia, an Italian motocross ... wear a neck brace during its racing competitions.  ...
Breaking Medicine Technology:The Armor1 Ankle Roll Guard is the New Breakthrough Solution for Ankle Sprain Prevention! 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 3
... an international generic pharmaceuticals company, today announced that it ... Administration to market Valacyclovir Hydrochloride Tablets.     ... generic equivalent of Valtrex® by GlaxoSmithKline, had US sales ... December 31, 2010, according to IMS Health.     ...
... 2011 Amgen (Nasdaq: AMGN ) today ... and fifth years of Prolia® (denosumab) treatment, postmenopausal women ... year-over-year increases in lumbar spine and total hip bone ... The overall adverse event profile was similar for the ...
Cached Medicine Technology:Actavis Receives Approval of Valacyclovir Hydrochloride Tablets in the U.S. 2Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Five Years of Treatment With Similar Safety Profile Observed in Pivotal Trial 2Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Five Years of Treatment With Similar Safety Profile Observed in Pivotal Trial 3Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Five Years of Treatment With Similar Safety Profile Observed in Pivotal Trial 4Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Five Years of Treatment With Similar Safety Profile Observed in Pivotal Trial 5Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Five Years of Treatment With Similar Safety Profile Observed in Pivotal Trial 6Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Five Years of Treatment With Similar Safety Profile Observed in Pivotal Trial 7Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Five Years of Treatment With Similar Safety Profile Observed in Pivotal Trial 8Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Five Years of Treatment With Similar Safety Profile Observed in Pivotal Trial 9
(Date:1/22/2015)... The City of West Hollywood hosted a news conference ... 42nd anniversary of the Supreme Court decision Roe v. Wade, which ... since the Roe vs. Wade decision and the fight to protect ... said City of West Hollywood Councilmember Abbe Land. “We need to ...
(Date:1/22/2015)... January 22, 2015 Padre Murphy's and Owner ... of Pro Player Health Alliance (PPHA). The PPHA's ... in getting everyone, including NFL greats, treated for obstructive sleep ... leading groups supporting the cause in the valley. The most ...
(Date:1/22/2015)... Angelweddingdress is a famous wedding dress company offering many trendy ... on Facebook, Twitter, and Pinterest. The fans will have an ... lottery every week. , Moreover, the company has extended its ... Angelweddingdress homepage for more information. , Angelweddingdress is ...
(Date:1/22/2015)... New York, New York (PRWEB) January 22, 2015 ... ( http://www.vaginalmeshlawsuit2015.com/ ) in the U.S. District Court, Southern District ... against C.R. Bard, Inc. in that proceeding’s first bellwether trial. ... defense request for a new trial after finding that C.R. ...
(Date:1/22/2015)... 22, 2015 Thousand of GranuFlo lawsuits ... recalled its GranuFlo and NaturaLyte dialysis concentrates continue to ... U.S. District Court, District of Massachusetts, Bernstein Liebhard LLP ... Court has remanded a case filed by the state ...
Breaking Medicine News(10 mins):Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4
... metastasis , , MONDAY, March 3 (HealthDay News) -- A ... stem cells can inhibit the growth and spread of ... by researchers at Northwestern University in Chicago. , The ... Proceedings of the National Academy of Sciences , ...
... Ronnie B. Martin, DO,FACOFP-dist. of Parker, Colo., will ... College of Osteopathic Family Physicians during the 45th ... in Denver, Colo., For more than 50 ... health and welfare of patients served by osteopathic,family ...
... searched for a novel cancer drug that activates a ... drug that kills the cancer without causing damage to ... at the University of Michigan Comprehensive Cancer Center have ... cell cultures at inhibiting the interaction between this protein, ...
... Tied Directly ... to Increased Production Efficiency, NEW ORLEANS, March 3 ... couldn,t previously be,solved, Waters Corporation (NYSE: WAT ) today ... Chemistry and,Applied Spectroscopy, March 2 - 6, 2008 in New ...
... 2008, AT 5 P.M. EST) A research team from ... University and Hospital in Taiwan have described for the first ... CAPON or NOS1AP, can disrupt normal heart rhythm. Until recently, ... or playing a role in heart function. , The study, ...
... 3, 2008) New high-throughput methods are revolutionizing ... of Cold Spring Harbor Protocols ( www.cshprotocols.org/TOCs/toc3_08.dtl ... turn genes on and off. Both methods are ... Spring Harbor Protocols ( www.cshprotocols.org ). , Our ...
Cached Medicine News:Health News:Embryonic Stem Cell Protein Inhibits Melanoma 2Health News:Ronnie B. Martin, DO, FACOFP-dist. to be Inaugurated as the 55th President of the ACOFP (2008-2009) 2Health News:Ronnie B. Martin, DO, FACOFP-dist. to be Inaugurated as the 55th President of the ACOFP (2008-2009) 3Health News:U-M researchers ID promising new cancer drug 2Health News:Waters UPLC and HDMS Ignite Scientific Ingenuity with New System Solutions at Pittcon 2008 2Health News:Waters UPLC and HDMS Ignite Scientific Ingenuity with New System Solutions at Pittcon 2008 3Health News:Waters UPLC and HDMS Ignite Scientific Ingenuity with New System Solutions at Pittcon 2008 4Health News:Waters UPLC and HDMS Ignite Scientific Ingenuity with New System Solutions at Pittcon 2008 5Health News:Waters UPLC and HDMS Ignite Scientific Ingenuity with New System Solutions at Pittcon 2008 6Health News:Researchers describe mechanisms by which capon gene causes heart rhythm disturbances 2Health News:Cold Spring Harbor Protocols features high-throughput methods for analyzing gene activity 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: